Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $3.8 million.

  • Caribou Biosciences' Accounts Payables rose 4068.05% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 4068.05%. This contributed to the annual value of $2.5 million for FY2024, which is 2064.1% down from last year.
  • Latest data reveals that Caribou Biosciences reported Accounts Payables of $3.8 million as of Q3 2025, which was up 4068.05% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Accounts Payables ranged from a high of $5.9 million in Q1 2024 and a low of $426000.0 during Q2 2022
  • Its 5-year average for Accounts Payables is $3.0 million, with a median of $3.2 million in 2023.
  • As far as peak fluctuations go, Caribou Biosciences' Accounts Payables tumbled by 8942.67% in 2022, and later skyrocketed by 94061.03% in 2023.
  • Over the past 5 years, Caribou Biosciences' Accounts Payables (Quarter) stood at $4.0 million in 2021, then plummeted by 71.28% to $1.1 million in 2022, then soared by 172.25% to $3.1 million in 2023, then decreased by 20.64% to $2.5 million in 2024, then soared by 53.63% to $3.8 million in 2025.
  • Its Accounts Payables was $3.8 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.9 million in Q1 2025.